primary antibodies against ciap1 ciap2 Search Results


99
Thermo Fisher smac 2f
Smac 2f, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+ciap1+ciap2/pmc02936695-151-4-53?v=Thermo+Fisher
Average 99 stars, based on 1 article reviews
smac 2f - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

90
SMAC Corp ciap1 protein
Ciap1 Protein, supplied by SMAC Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+ciap1+ciap2/pm24789756-79-17-26?v=SMAC+Corp
Average 90 stars, based on 1 article reviews
ciap1 protein - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
OriGene ciap1 cdnas
Ciap1 Cdnas, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+ciap1+ciap2/pmc04400372-145-2-7?v=OriGene
Average 90 stars, based on 1 article reviews
ciap1 cdnas - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

93
R&D Systems ciap1
Ciap1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+ciap1+ciap2/pm25275296-145-18-19?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
ciap1 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

93
R&D Systems pan specific anti ciap1 2 mab3400
Pan Specific Anti Ciap1 2 Mab3400, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+ciap1+ciap2/pmc04276503-82-36-40?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
pan specific anti ciap1 2 mab3400 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

93
Proteintech ciap1
Relative mRNA expression of associated genes after TNFα and CHX stimulation.
Ciap1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+ciap1+ciap2/pmc08035156-317-91-94?v=Proteintech
Average 93 stars, based on 1 article reviews
ciap1 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

90
OriGene wild type birc3
Stereospecificity of NPD1 bioactivity selectively upregulates <t>BIRC3</t> expression. ( a ) BIRC1 to 8 in response to 600 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 100 nM NPD1 at 2, 4 and 6 h of treatment. ( b ) BIRC3 mRNA expression in response to 100 nM maresin 1, lipoxin-A4 and RvE1 along with NPD1 and its stereoisomers SS-NPD1 and RR-NPD1 and ( c ) in an siRNA dose-dependent curve. ARPE-19 cells were transfected with 0, 5, 10, 20, 50 and 100 pmol of siRNA per ml of culture media and treated with 400 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 100 nM NPD1. ( i – vi ) Structure of the lipid mediators used in ( b ). The bars represent the mean of three triplicates ± standard error. * P <0.05, NS=non-significant P- value. NPD1-treated samples=blue bars; OS+NPD1=light blue bars
Wild Type Birc3, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+ciap1+ciap2/pmc04495360-152-0-9?v=OriGene
Average 90 stars, based on 1 article reviews
wild type birc3 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

93
R&D Systems anti goat human ciap 1
Stereospecificity of NPD1 bioactivity selectively upregulates <t>BIRC3</t> expression. ( a ) BIRC1 to 8 in response to 600 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 100 nM NPD1 at 2, 4 and 6 h of treatment. ( b ) BIRC3 mRNA expression in response to 100 nM maresin 1, lipoxin-A4 and RvE1 along with NPD1 and its stereoisomers SS-NPD1 and RR-NPD1 and ( c ) in an siRNA dose-dependent curve. ARPE-19 cells were transfected with 0, 5, 10, 20, 50 and 100 pmol of siRNA per ml of culture media and treated with 400 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 100 nM NPD1. ( i – vi ) Structure of the lipid mediators used in ( b ). The bars represent the mean of three triplicates ± standard error. * P <0.05, NS=non-significant P- value. NPD1-treated samples=blue bars; OS+NPD1=light blue bars
Anti Goat Human Ciap 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+ciap1+ciap2/pmc03682510-235-37-40?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
anti goat human ciap 1 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

94
Proteintech rabbit proteintech anti ciap1
Stereospecificity of NPD1 bioactivity selectively upregulates <t>BIRC3</t> expression. ( a ) BIRC1 to 8 in response to 600 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 100 nM NPD1 at 2, 4 and 6 h of treatment. ( b ) BIRC3 mRNA expression in response to 100 nM maresin 1, lipoxin-A4 and RvE1 along with NPD1 and its stereoisomers SS-NPD1 and RR-NPD1 and ( c ) in an siRNA dose-dependent curve. ARPE-19 cells were transfected with 0, 5, 10, 20, 50 and 100 pmol of siRNA per ml of culture media and treated with 400 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 100 nM NPD1. ( i – vi ) Structure of the lipid mediators used in ( b ). The bars represent the mean of three triplicates ± standard error. * P <0.05, NS=non-significant P- value. NPD1-treated samples=blue bars; OS+NPD1=light blue bars
Rabbit Proteintech Anti Ciap1, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+ciap1+ciap2/pmc10646551__EMBJ___42___e113614___s001-0-135-136?v=Proteintech
Average 94 stars, based on 1 article reviews
rabbit proteintech anti ciap1 - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

86
Thermo Fisher gene exp birc2 hs00236911 m1
Stereospecificity of NPD1 bioactivity selectively upregulates <t>BIRC3</t> expression. ( a ) BIRC1 to 8 in response to 600 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 100 nM NPD1 at 2, 4 and 6 h of treatment. ( b ) BIRC3 mRNA expression in response to 100 nM maresin 1, lipoxin-A4 and RvE1 along with NPD1 and its stereoisomers SS-NPD1 and RR-NPD1 and ( c ) in an siRNA dose-dependent curve. ARPE-19 cells were transfected with 0, 5, 10, 20, 50 and 100 pmol of siRNA per ml of culture media and treated with 400 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 100 nM NPD1. ( i – vi ) Structure of the lipid mediators used in ( b ). The bars represent the mean of three triplicates ± standard error. * P <0.05, NS=non-significant P- value. NPD1-treated samples=blue bars; OS+NPD1=light blue bars
Gene Exp Birc2 Hs00236911 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+ciap1+ciap2/pm23340716-93-20--1?v=Thermo+Fisher
Average 86 stars, based on 1 article reviews
gene exp birc2 hs00236911 m1 - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

90
ProSci Incorporated antibodies against ciap
Stereospecificity of NPD1 bioactivity selectively upregulates <t>BIRC3</t> expression. ( a ) BIRC1 to 8 in response to 600 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 100 nM NPD1 at 2, 4 and 6 h of treatment. ( b ) BIRC3 mRNA expression in response to 100 nM maresin 1, lipoxin-A4 and RvE1 along with NPD1 and its stereoisomers SS-NPD1 and RR-NPD1 and ( c ) in an siRNA dose-dependent curve. ARPE-19 cells were transfected with 0, 5, 10, 20, 50 and 100 pmol of siRNA per ml of culture media and treated with 400 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 100 nM NPD1. ( i – vi ) Structure of the lipid mediators used in ( b ). The bars represent the mean of three triplicates ± standard error. * P <0.05, NS=non-significant P- value. NPD1-treated samples=blue bars; OS+NPD1=light blue bars
Antibodies Against Ciap, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+ciap1+ciap2/pmc03530008-50-0-16?v=ProSci+Incorporated
Average 90 stars, based on 1 article reviews
antibodies against ciap - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
SMAC Corp smac mimetic lcl161
Status of different Smac mimetics
Smac Mimetic Lcl161, supplied by SMAC Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+ciap1+ciap2/pmc07001279-76-36-34?v=SMAC+Corp
Average 90 stars, based on 1 article reviews
smac mimetic lcl161 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Relative mRNA expression of associated genes after TNFα and CHX stimulation.

Journal: Cell Death & Disease

Article Title: Cellular FLICE-like inhibitory protein (cFLIP) critically maintains apoptotic resistance in human lens epithelial cells

doi: 10.1038/s41419-021-03683-y

Figure Lengend Snippet: Relative mRNA expression of associated genes after TNFα and CHX stimulation.

Article Snippet: The membrane was first blocked by 5% non-fat milk tris buffer saline plus tween 20 (PBST) for an hour at room temperature and then probed with primary antibodies of caspase-8 (Cat. 645501, Biolegend), pro-caspase 8, mouse-specific (Cat. 4927, Cell Signaling, Danvers, MA), caspase-9 (Cat. 9502, Cell Signaling), cleaved caspase 8, mouse-specific (Cat. 8592, Cell Signaling), caspase-3 (Cat. 74T2, ThermoFisher), cleaved caspase-3 (Cat. 9664, Cell Signaling), PAPR-1 (Cat. 13371-1-AP, Proteintech), cFLIP (Cat. No. 10394-1-AP, Proteintech, Rosemont, IL), cFLIP for mouse cells and tissue (AF821, R&D System, Minneapolis, MN), Survivin (Cat. 1058-1-AP, Proteintech), CIAP1 (Cat. 66626-1-AP, Proteintech), CIAP2 (Cat. 24304-1-AP, Proteintech), XIAP (Cat. 10037-1-lg, Proteintech), GAPDH (Cat. PA1-987, ThermoFisher) overnight at 4 °C.

Techniques: Expressing

Stereospecificity of NPD1 bioactivity selectively upregulates BIRC3 expression. ( a ) BIRC1 to 8 in response to 600 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 100 nM NPD1 at 2, 4 and 6 h of treatment. ( b ) BIRC3 mRNA expression in response to 100 nM maresin 1, lipoxin-A4 and RvE1 along with NPD1 and its stereoisomers SS-NPD1 and RR-NPD1 and ( c ) in an siRNA dose-dependent curve. ARPE-19 cells were transfected with 0, 5, 10, 20, 50 and 100 pmol of siRNA per ml of culture media and treated with 400 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 100 nM NPD1. ( i – vi ) Structure of the lipid mediators used in ( b ). The bars represent the mean of three triplicates ± standard error. * P <0.05, NS=non-significant P- value. NPD1-treated samples=blue bars; OS+NPD1=light blue bars

Journal: Cell Death and Differentiation

Article Title: NPD1-mediated stereoselective regulation of BIRC3 expression through cREL is decisive for neural cell survival

doi: 10.1038/cdd.2014.233

Figure Lengend Snippet: Stereospecificity of NPD1 bioactivity selectively upregulates BIRC3 expression. ( a ) BIRC1 to 8 in response to 600 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 100 nM NPD1 at 2, 4 and 6 h of treatment. ( b ) BIRC3 mRNA expression in response to 100 nM maresin 1, lipoxin-A4 and RvE1 along with NPD1 and its stereoisomers SS-NPD1 and RR-NPD1 and ( c ) in an siRNA dose-dependent curve. ARPE-19 cells were transfected with 0, 5, 10, 20, 50 and 100 pmol of siRNA per ml of culture media and treated with 400 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 100 nM NPD1. ( i – vi ) Structure of the lipid mediators used in ( b ). The bars represent the mean of three triplicates ± standard error. * P <0.05, NS=non-significant P- value. NPD1-treated samples=blue bars; OS+NPD1=light blue bars

Article Snippet: Wild-type BIRC3-, cREL- and cREL-fused-with-GFP-expression constructs were obtained from Origene.

Techniques: Expressing, Transfection

TNFR1 stably-silenced cells display enhanced BIRC3 expression and cell survival upon oxidative stress (OS). ( a and b ) TNFR1 and NC shRNA-expressing ARPE-19 cells were subjected to OS in the presence or absence of NPD1. ( a ) Representative pictures and ( b ) quantification of apoptotic TNFR1 and NC shRNA-expressing cells in the presence or absence of 50 nM NPD1. ( c ) BIRC3 expression induced by NPD1 upon OS by the means of real-time PCR in TNFR1-deficient cells. ( d and e ) Western blot showing the time-dependent phosphorylation of ( d ) I k B α and ( e ) I k B β after 0, 15, 30 and 60 min of OS treatment in the presence or absence of 100 nM NPD1. ( f ) NPD1 effects on canonical NF- κ B activation measured by the means of luciferase reporter assay in OS conditions. OS: 600 μ M H 2 O 2 /10 ng/ml TNF- α . NPD1: 100 nM. Bars represent the mean of triplicates ± standard error of the mean. * P <0.05, NS=non-significant P -value. NPD1 treated samples=blue bars; OS+NPD1=light blue bars

Journal: Cell Death and Differentiation

Article Title: NPD1-mediated stereoselective regulation of BIRC3 expression through cREL is decisive for neural cell survival

doi: 10.1038/cdd.2014.233

Figure Lengend Snippet: TNFR1 stably-silenced cells display enhanced BIRC3 expression and cell survival upon oxidative stress (OS). ( a and b ) TNFR1 and NC shRNA-expressing ARPE-19 cells were subjected to OS in the presence or absence of NPD1. ( a ) Representative pictures and ( b ) quantification of apoptotic TNFR1 and NC shRNA-expressing cells in the presence or absence of 50 nM NPD1. ( c ) BIRC3 expression induced by NPD1 upon OS by the means of real-time PCR in TNFR1-deficient cells. ( d and e ) Western blot showing the time-dependent phosphorylation of ( d ) I k B α and ( e ) I k B β after 0, 15, 30 and 60 min of OS treatment in the presence or absence of 100 nM NPD1. ( f ) NPD1 effects on canonical NF- κ B activation measured by the means of luciferase reporter assay in OS conditions. OS: 600 μ M H 2 O 2 /10 ng/ml TNF- α . NPD1: 100 nM. Bars represent the mean of triplicates ± standard error of the mean. * P <0.05, NS=non-significant P -value. NPD1 treated samples=blue bars; OS+NPD1=light blue bars

Article Snippet: Wild-type BIRC3-, cREL- and cREL-fused-with-GFP-expression constructs were obtained from Origene.

Techniques: Stable Transfection, Expressing, shRNA, Real-time Polymerase Chain Reaction, Western Blot, Activation Assay, Luciferase, Reporter Assay

NPD1-mediated BIRC3 promoter activation. BIRC3 promoter was analyzed using a luciferase reporter assay. ( a ) Schematic representation of the constructs used for deletion and mutation. ( b ) BIRC3 promoter deletion analysis using constructs containing 527, 247, 200, 174 and 93 bp (depicted in a ) upstream of the transcription start site. Transfected cells were treated with 130 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 200 nM NPD1. ( c ) Site directed mutation analysis on the NF- κ B sites. Cells were treated with 400 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 200 nM NPD1. ( d ) Luciferase activity was standardized by GFP fluorescence. Bars represent the mean of triplicates ± standard error of the mean. * P <0.05, NS=non-significant P- value. NPD1-treated samples=blue bars; OS+NPD1=light blue bars

Journal: Cell Death and Differentiation

Article Title: NPD1-mediated stereoselective regulation of BIRC3 expression through cREL is decisive for neural cell survival

doi: 10.1038/cdd.2014.233

Figure Lengend Snippet: NPD1-mediated BIRC3 promoter activation. BIRC3 promoter was analyzed using a luciferase reporter assay. ( a ) Schematic representation of the constructs used for deletion and mutation. ( b ) BIRC3 promoter deletion analysis using constructs containing 527, 247, 200, 174 and 93 bp (depicted in a ) upstream of the transcription start site. Transfected cells were treated with 130 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 200 nM NPD1. ( c ) Site directed mutation analysis on the NF- κ B sites. Cells were treated with 400 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 200 nM NPD1. ( d ) Luciferase activity was standardized by GFP fluorescence. Bars represent the mean of triplicates ± standard error of the mean. * P <0.05, NS=non-significant P- value. NPD1-treated samples=blue bars; OS+NPD1=light blue bars

Article Snippet: Wild-type BIRC3-, cREL- and cREL-fused-with-GFP-expression constructs were obtained from Origene.

Techniques: Activation Assay, Luciferase, Reporter Assay, Construct, Mutagenesis, Transfection, Activity Assay, Fluorescence

cREL nuclear translocation and binding to BIRC3 promoter to induce the activation of its expression. Changes of distribution, activity and expression of cRel were assessed at three time points (2, 4 and 6 h) in ARPE-19 cells treated with 400 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 100 nM NPD1. ( a – c ) Immunocytochemistry of cREL in cells: ( a ) representative pictures showing the distribution of the cREL signal (red). Nuclei were stained with DAPI (blue). ( b and c ) Portion of cells depicting cREL nuclear or cytoplasmic signal. ( d and e ) cREL protein content evaluated by western blot ( d ) in the nuclear fraction standardized using TBP at 2 h and ( e ) in whole cells standardized by GAPDH after 4 h of OS or OS+NPD1. ( f ) ChiP assay at 4 h showing the binding of cREL to BIRC3 promoter. The co-immunoprecipitated genomic DNA was amplified and standardized by the input. ( g ) Co-immunoprecipitation of cREL and p65/RelA at 4 h of treatment standardized by GAPDH. ( h ) p65/RelA, RelB and cRel expression determined by real-time PCR. ( i – k ) Silencing of cRel induced changes in the expression of: ( i ) cREL, ( j ) RelB and ( k ) BIRC3 in human RPE (hRPE) cells established by the means of real-time PCR. Concentrations of 2.5, 10 and 50 pmol siRNA per ml of cell culture medium were used to show a concentration-dependent effect on the expression at 4 h. ( l and m ) Schematization of the temporal pattern of ( l ) cREL, RelB and BIRC3 expression and ( m ) cREL translocation. The values are represented as the mean of triplicates ± the standard error. * P <0.05, NS=non-significant P- value. NPD1-treated samples=blue bars; OS+NPD1=light blue bars

Journal: Cell Death and Differentiation

Article Title: NPD1-mediated stereoselective regulation of BIRC3 expression through cREL is decisive for neural cell survival

doi: 10.1038/cdd.2014.233

Figure Lengend Snippet: cREL nuclear translocation and binding to BIRC3 promoter to induce the activation of its expression. Changes of distribution, activity and expression of cRel were assessed at three time points (2, 4 and 6 h) in ARPE-19 cells treated with 400 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of 100 nM NPD1. ( a – c ) Immunocytochemistry of cREL in cells: ( a ) representative pictures showing the distribution of the cREL signal (red). Nuclei were stained with DAPI (blue). ( b and c ) Portion of cells depicting cREL nuclear or cytoplasmic signal. ( d and e ) cREL protein content evaluated by western blot ( d ) in the nuclear fraction standardized using TBP at 2 h and ( e ) in whole cells standardized by GAPDH after 4 h of OS or OS+NPD1. ( f ) ChiP assay at 4 h showing the binding of cREL to BIRC3 promoter. The co-immunoprecipitated genomic DNA was amplified and standardized by the input. ( g ) Co-immunoprecipitation of cREL and p65/RelA at 4 h of treatment standardized by GAPDH. ( h ) p65/RelA, RelB and cRel expression determined by real-time PCR. ( i – k ) Silencing of cRel induced changes in the expression of: ( i ) cREL, ( j ) RelB and ( k ) BIRC3 in human RPE (hRPE) cells established by the means of real-time PCR. Concentrations of 2.5, 10 and 50 pmol siRNA per ml of cell culture medium were used to show a concentration-dependent effect on the expression at 4 h. ( l and m ) Schematization of the temporal pattern of ( l ) cREL, RelB and BIRC3 expression and ( m ) cREL translocation. The values are represented as the mean of triplicates ± the standard error. * P <0.05, NS=non-significant P- value. NPD1-treated samples=blue bars; OS+NPD1=light blue bars

Article Snippet: Wild-type BIRC3-, cREL- and cREL-fused-with-GFP-expression constructs were obtained from Origene.

Techniques: Translocation Assay, Binding Assay, Activation Assay, Expressing, Activity Assay, Immunocytochemistry, Staining, Western Blot, Immunoprecipitation, Amplification, Real-time Polymerase Chain Reaction, Cell Culture, Concentration Assay

NPD1 fails to rescue BIRC3 silenced cells. ( a – e ) Apoptosis noted as percentage of Hoechst- or TUNEL-positive cells was assessed on ARPE-19 ( a – c ) or primary human RPE (hRPE) cells ( d and e ). ( a ) Representative images of TUNEL staining performed on ARPE-19 cells, ( b and c ) Quantification of TUNEL and Hoechst-positive cells when transfected with BIRC3 or control siRNA and treated with 0, 400 and 600 μ M H 2 O 2 /10 ng/ml TNF- α with or without 200 nM NPD1. BIRC3 ( d ), cREL ( e ) or control siRNA-transfected hRPE cells treated with 600 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of NPD1 100 nM. cREL and BIRC3 ( f ) and BIRC3 ( g ) protein content when cREL and BIRC3, respectively, were overexpressed. ( h ) Percentage of apoptosis in ARPE-19 cells overexpressing cREL or BIRC3 when confronted with OS in the presence or absence of NPD1. ( i and j ) Overexpression of ( i ) cREL or ( j ) BIRC3 using a wild-type open reading frame (ORF) or one carrying silent mutations at the siRNAs binding sites (ORFmut) to prevent its silencing and rescue from the knocked down phenotype. Upper panels show representative western blots for the corresponding protein content in each sample. Lower panels depict percentage of apoptosis for each treatment. ( k and l ) Activation of effector caspases 3 and 7 as a result of OS treatment in BIRC3-silenced cells. ( k ) Representative nuclei and staining of cells: upper panel, control; lower panel, OS. ( m and n ) Apoptosis and necrosis measured by the means of AnnexinV and 7-Amino actinomycinD when cells were treated with OS and NPD1 in the presence of z-VAD, a pan caspase inhibitor or Necrostatin 1 (Nec1). ( o ) cREL translocation (upper panel) and percentage of apoptosis of control and cREL-silenced (lower panel) ARPE-19 cells subjected to OS with the addition NPD1 or DHA plus 10 ng/ml of PEDF, FGF, CNTF or BDNF to endogenously induce NPD1 synthesis. ( p ) Schematization of the model obtained by the integration of the data obtained in this report and the context. Bars represent the mean of triplicates + standard error of the mean. * P <0.05 NS=non-significant P -value. NPD1-treated samples=blue bars; OS+NPD1=light blue bars; DHA+growth factors=teal bars; OS+DHA+growth factors=light teal bars

Journal: Cell Death and Differentiation

Article Title: NPD1-mediated stereoselective regulation of BIRC3 expression through cREL is decisive for neural cell survival

doi: 10.1038/cdd.2014.233

Figure Lengend Snippet: NPD1 fails to rescue BIRC3 silenced cells. ( a – e ) Apoptosis noted as percentage of Hoechst- or TUNEL-positive cells was assessed on ARPE-19 ( a – c ) or primary human RPE (hRPE) cells ( d and e ). ( a ) Representative images of TUNEL staining performed on ARPE-19 cells, ( b and c ) Quantification of TUNEL and Hoechst-positive cells when transfected with BIRC3 or control siRNA and treated with 0, 400 and 600 μ M H 2 O 2 /10 ng/ml TNF- α with or without 200 nM NPD1. BIRC3 ( d ), cREL ( e ) or control siRNA-transfected hRPE cells treated with 600 μ M H 2 O 2 /10 ng/ml TNF- α in the presence or absence of NPD1 100 nM. cREL and BIRC3 ( f ) and BIRC3 ( g ) protein content when cREL and BIRC3, respectively, were overexpressed. ( h ) Percentage of apoptosis in ARPE-19 cells overexpressing cREL or BIRC3 when confronted with OS in the presence or absence of NPD1. ( i and j ) Overexpression of ( i ) cREL or ( j ) BIRC3 using a wild-type open reading frame (ORF) or one carrying silent mutations at the siRNAs binding sites (ORFmut) to prevent its silencing and rescue from the knocked down phenotype. Upper panels show representative western blots for the corresponding protein content in each sample. Lower panels depict percentage of apoptosis for each treatment. ( k and l ) Activation of effector caspases 3 and 7 as a result of OS treatment in BIRC3-silenced cells. ( k ) Representative nuclei and staining of cells: upper panel, control; lower panel, OS. ( m and n ) Apoptosis and necrosis measured by the means of AnnexinV and 7-Amino actinomycinD when cells were treated with OS and NPD1 in the presence of z-VAD, a pan caspase inhibitor or Necrostatin 1 (Nec1). ( o ) cREL translocation (upper panel) and percentage of apoptosis of control and cREL-silenced (lower panel) ARPE-19 cells subjected to OS with the addition NPD1 or DHA plus 10 ng/ml of PEDF, FGF, CNTF or BDNF to endogenously induce NPD1 synthesis. ( p ) Schematization of the model obtained by the integration of the data obtained in this report and the context. Bars represent the mean of triplicates + standard error of the mean. * P <0.05 NS=non-significant P -value. NPD1-treated samples=blue bars; OS+NPD1=light blue bars; DHA+growth factors=teal bars; OS+DHA+growth factors=light teal bars

Article Snippet: Wild-type BIRC3-, cREL- and cREL-fused-with-GFP-expression constructs were obtained from Origene.

Techniques: TUNEL Assay, Staining, Transfection, Over Expression, Binding Assay, Western Blot, Activation Assay, Translocation Assay

BIRC3 mediates the pro-survival response induced by the DHA/NPD1 pathway in an ischemia-reperfusion stroke model. ( a – c ) Model for inducing ischemia-reperfusion by middle cerebral artery occlusion (MCAo) in rats. ( a ) Timeline showing surgery, treatment and tests performed. ( b ) Coronal brain diagram (bregma level –0.3 mm) showing locations of regions for western blot and immunohistochemistry for , and lipidomic analysis (A: anterior; P: posterior). ( c ) Diagram of MCAo model obtained by introducing intraluminal filament (red). ( d ) Total neurological score (normal score =0, maximal deficit=12), tactile placing (proprioceptive, lateral, dorsal reactions; normal score=0, maximal deficit=2) in rats after MCAo. DHA treatment improved the total and placing deficits on days 1, 3 and 7 compared with the saline-treated group. ( e ) Content of NPD1 and a second product of the stabilized precursor, 17HDHA, in penumbra regions of rats subjected to MCAo and treated with DHA or vehicle as a control. Data are means±standard error of the mean; n =6 per group. * P <0.05 in repeated-measures, ANOVA followed by Bonferroni test. DHA treatment=teal bars

Journal: Cell Death and Differentiation

Article Title: NPD1-mediated stereoselective regulation of BIRC3 expression through cREL is decisive for neural cell survival

doi: 10.1038/cdd.2014.233

Figure Lengend Snippet: BIRC3 mediates the pro-survival response induced by the DHA/NPD1 pathway in an ischemia-reperfusion stroke model. ( a – c ) Model for inducing ischemia-reperfusion by middle cerebral artery occlusion (MCAo) in rats. ( a ) Timeline showing surgery, treatment and tests performed. ( b ) Coronal brain diagram (bregma level –0.3 mm) showing locations of regions for western blot and immunohistochemistry for , and lipidomic analysis (A: anterior; P: posterior). ( c ) Diagram of MCAo model obtained by introducing intraluminal filament (red). ( d ) Total neurological score (normal score =0, maximal deficit=12), tactile placing (proprioceptive, lateral, dorsal reactions; normal score=0, maximal deficit=2) in rats after MCAo. DHA treatment improved the total and placing deficits on days 1, 3 and 7 compared with the saline-treated group. ( e ) Content of NPD1 and a second product of the stabilized precursor, 17HDHA, in penumbra regions of rats subjected to MCAo and treated with DHA or vehicle as a control. Data are means±standard error of the mean; n =6 per group. * P <0.05 in repeated-measures, ANOVA followed by Bonferroni test. DHA treatment=teal bars

Article Snippet: Wild-type BIRC3-, cREL- and cREL-fused-with-GFP-expression constructs were obtained from Origene.

Techniques: Western Blot, Immunohistochemistry

DHA/NPD1 induce translocation of cREL and increased BIRC3 in vivo . ( a ) Western blot on days 1, 3 and 7 after DHA treatment performed on the posterior section. ( b – e ) Translocation of cREL in neurons of the penumbra, areas A1-3 and P1-3 (see ). ( b ) Representative images of nuclear translocation of cREL in saline- and DHA-treated animals in the P2 region 1 day after treatment. (NeuN red; c-REL green). ( c ) High magnification. cREL ( d ) total (upper panels) and ( e ) nuclear (lower panels) quantification from areas A1 to 3 (upper panels) and P1-3 (lower panels). ( f ) BIRC3 (red) and NeuN (green), and ( g ) BIRC3 (red) and GFAP (green) double staining on day 1 after stroke. ( h ) Quantification of the co-localization studies in ( f and g) . Data are means±S.E.M.; n =6 per group. * P <0.05 in repeated-measures, ANOVA followed by Bonferroni test. DHA treatment=teal bars

Journal: Cell Death and Differentiation

Article Title: NPD1-mediated stereoselective regulation of BIRC3 expression through cREL is decisive for neural cell survival

doi: 10.1038/cdd.2014.233

Figure Lengend Snippet: DHA/NPD1 induce translocation of cREL and increased BIRC3 in vivo . ( a ) Western blot on days 1, 3 and 7 after DHA treatment performed on the posterior section. ( b – e ) Translocation of cREL in neurons of the penumbra, areas A1-3 and P1-3 (see ). ( b ) Representative images of nuclear translocation of cREL in saline- and DHA-treated animals in the P2 region 1 day after treatment. (NeuN red; c-REL green). ( c ) High magnification. cREL ( d ) total (upper panels) and ( e ) nuclear (lower panels) quantification from areas A1 to 3 (upper panels) and P1-3 (lower panels). ( f ) BIRC3 (red) and NeuN (green), and ( g ) BIRC3 (red) and GFAP (green) double staining on day 1 after stroke. ( h ) Quantification of the co-localization studies in ( f and g) . Data are means±S.E.M.; n =6 per group. * P <0.05 in repeated-measures, ANOVA followed by Bonferroni test. DHA treatment=teal bars

Article Snippet: Wild-type BIRC3-, cREL- and cREL-fused-with-GFP-expression constructs were obtained from Origene.

Techniques: Translocation Assay, In Vivo, Western Blot, Double Staining

Status of different Smac mimetics

Journal: Journal of Biomedical Science

Article Title: Anti-apoptotic proteins in the autophagic world: an update on functions of XIAP, Survivin, and BRUCE

doi: 10.1186/s12929-020-0627-5

Figure Lengend Snippet: Status of different Smac mimetics

Article Snippet: Even though targeting IAPs including XIAP, cIAP1, and cIAP2 by a Smac mimetic, APG-1387, was shown to induce autophagy and cell death in human ovarian cancer cells [ ]; contrary, addition of a different Smac mimetic, LCL161 (a drug known to target cIAP1, cIAP2, and XIAP), at high dose was shown to inhibit the fusion between autophagosome and lysosome in mouse embryonic cells (MEFs) [ ].

Techniques: